Back to results
US 2026/0242329 A1Published application
An improved process for the preparation of intermediates used in the preparation of dasatinib
AssigneeOcimum Labs Private Limited
InventorsHarikrishna Mudduluru, Munisekhar Reddy Sannareddy, Salivahanaiah Akkili, Mahender Reddy Marri
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved process for the preparation of intermediate compounds used in the preparation of Dasatinib. The present invention specifically relates to an improved process for the preparation of intermediate compound of Formula (I) used in the preparation of Dasatinib or its pharmaceutically acceptable salts.
Claims9
1:
- An improved process for the preparation of intermediate compound of Formula (I)
- which comprises:
- a) providing the sodium salt of 4-acetamido-3-methyl benzenesulphonate compound of Formula (II)
- and reacting with chlorinating agent, and oxone in the presence or absence of a polar solvent to obtain an intermediate compound of Formula (III),
- b) hydrolysing the acyl group of intermediate compound of Formula (I) using an acid to produce the intermediate compound of Formula (IV),
- c) desulphonation of intermediate compound of Formula (IV) using an acid in solvent and extraction of the product using a solvent to produce the intermediate compound of Formula (I).
3 more elements
2:
- An improved process for the preparation of intermediate compound of Formula (I)
- which comprises:
- a) providing the sodium salt of 4-acetamido-3-methyl benzenesulphonate compound of Formula (II)
- and reacting with chlorinating agent, concentrated hydrochloric acid and Oxone® to obtain an intermediate compound of Formula (III),
- b) hydrolysing the acyl group of intermediate compound of Formula (I) using concentrated hydrochloric acid to produce the intermediate compound of Formula (IV),
- c) desulphonation of intermediate compound of Formula (IV) using concentrated hydrochloric acid in sulfolane solvent and extraction of the product in dichloromethane to produce the intermediate compound of Formula (I).
3 more elements
3:
- The process as claimed in claim 1, wherein the intermediate compound of formula (I) is utilised in the preparation of Dasatinib or its pharmaceutically acceptable salts of Formula (V)
4:
- The process as claimed in claim 1, wherein the chlorinating agent is HCl, NaCl, KCl, NH4Cl.
5:
- The process as claimed in claim 1, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butano, t-butanol, benzene, toluene, xylene, heptane, hexane, acetone, ethyl methyl ketone, diethyl ketone, methyl tert-butyl ketone, isopropyl ketone, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, sec-butyl acetate, acetonitrile, propionitrile, butyronitrile and isobutyronitrile, di-tert-butylether, dimethylether, diethylether, diisopropyl ether, 1,4-dioxane, methyltert-butylether, ethyl tert-butyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, 2-methoxyethanol, dimethoxyethane, formamide, DMF, DMAC, N-methyl-2-pyrrolidone, N-methylformamide, 2-pyrrolidone, 1-ethenyl-2-pyrrolidone, dichloromethane, 1,2-dichloroethane, chloroform, diethylenetriamine, ethylenediamine, morpholine, piperidine, pyridine, quinoline, tributylamine, diisopropyl amine, sulfolane and water.
6:
- The solvent as claimed in claim 5, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butano, t-butanol, acetonitrile, propionitrile, butyronitrile, isobutyronitrile, dichloromethane, 1,2-dichloroethane, chloroform, sulfolane and water.
7:
- The process as claimed in claim 1, wherein the hydrolysis is carried out using conc. HCl, H2SO4 and H3PO4.
8:
- The process as claimed in claim 1, wherein the desulphonation is carried out using acid selected from HCl, H2SO4 and H3PO4.
9:
- The process as claimed in claim 2, wherein the intermediate compound of formula (I) is utilised in the preparation of Dasatinib
- or its pharmaceutically acceptable salts of Formula (V)